Wu Pengfei, Zhang Yuhang, Zhu Shiyao, Wang Mo, Zhou Peng, Wang Guishuan, Li Wenqing
Institute of Reproductive Medicine, School of Medicine, Nantong University Nantong 226000 China
RSC Adv. 2023 Mar 13;13(11):7656-7663. doi: 10.1039/d2ra08148b. eCollection 2023 Mar 1.
Few nanomedicines are approved for clinical cancer treatment as only about 0.7% (median) of nanoparticles enter solid tumors. Nanomedicine as the second medication is usually used in cancer treatment after chemotherapy, immunotherapy surgery, or radiotherapy treatment. However, it is currently unpredictable whether the priority treatment enhances or reduces the therapeutic effect of nanomedicine. Here, by considering prior chemotherapy (5-FU or cisplatin treatment), immunotherapy (IL-2, IL-6, or IL-21-treatment), or phosphate-buffered saline (PBS treatment), we compared the biodistribution of AuNPs in the liver, spleen, kidney, and tumor. We found that the accumulation of AuNPs in the liver and spleen increased in cisplatin pretreatment compared to the PBS treatment, while there was no significant effect on the accumulation of AuNPs in the tumor due to cisplatin-induced significant liver damage while other treatments did not change the biodistribution of AuNPs in the liver, spleen, kidney, and tumor. These results indicated that cisplatin pretreatment is not suitable for subsequent nanomedical cancer therapy. Our work opens a new insight to design low-toxicity chemotherapy to be applied before nanomedicine.
由于只有约0.7%（中位数）的纳米颗粒能够进入实体瘤，因此获批用于临床癌症治疗的纳米药物很少。纳米药物作为二线药物，通常在化疗、免疫疗法、手术或放射治疗之后用于癌症治疗。然而，目前尚无法预测优先治疗是会增强还是降低纳米药物的治疗效果。在此，通过考虑先前的化疗（5-氟尿嘧啶或顺铂治疗）、免疫疗法（白细胞介素-2、白细胞介素-6或白细胞介素-21治疗）或磷酸盐缓冲盐水（PBS治疗），我们比较了金纳米颗粒在肝脏、脾脏、肾脏和肿瘤中的生物分布。我们发现，与PBS治疗相比，顺铂预处理后肝脏和脾脏中金纳米颗粒的积累增加，而由于顺铂引起的严重肝损伤，顺铂对肿瘤中金纳米颗粒的积累没有显著影响，而其他治疗并未改变金纳米颗粒在肝脏、脾脏、肾脏和肿瘤中的生物分布。这些结果表明，顺铂预处理不适用于随后的纳米医学癌症治疗。我们的工作为设计在纳米药物之前应用的低毒性化疗开辟了新的思路。
